- Home
- ASPI vs GHRS Comparison
ASPI vs GHRS Comparison
Compare ASPI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASPI | GHRS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ASPI | GHRS |
|---|---|---|
| Price | $6.55 | $21.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $12.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 5.8M | 245.5K |
| Earning Date | 04-10-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,849,000.00 | N/A |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $11.32 |
| 52 Week High | $14.49 | $25.94 |
Technical Indicators
Market Signals| Indicator | ASPI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 48.83 |
| Support Level | $4.84 | $12.79 |
| Resistance Level | $8.41 | $22.88 |
| Average True Range (ATR) | 0.76 | 1.73 |
| MACD | -0.16 | -0.46 |
| Stochastic Oscillator | 30.72 | 25.32 |
Price Performance
Historical ComparisonAbout ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.